Moderna and Partners Receive $60 Million to Advance Ebola Vaccine Development

A consortium including Moderna and other research groups has secured around $60 million in funding to accelerate the development of a next-generation Ebola vaccine, amid renewed concerns over outbreaks in parts of Africa.

The funding is aimed at advancing vaccine candidates through preclinical work and early-stage clinical trials, with a focus on improving speed of response and immune protection against Ebola virus disease.

The project includes work on mRNA-based vaccine technology, an approach that gained global attention during the COVID-19 pandemic and is now being adapted for high-risk infectious diseases such as Ebola.

Researchers say the goal is to develop a vaccine that can be deployed more rapidly during outbreaks, particularly in remote or high-risk regions where containment is difficult.

The investment comes as health authorities and organisations such as the World Health Organization (WHO) monitor new Ebola cases in parts of Central and East Africa.

Experts warn that recurring outbreaks continue to expose gaps in global preparedness, particularly in rapid vaccine deployment and healthcare infrastructure in affected regions.

Health officials say improving Ebola vaccine technology is critical for preventing small outbreaks from escalating into larger epidemics.

The new funding is expected to support research collaboration between biotech firms, academic institutions, and global health agencies.

Early-stage trials and laboratory development are expected to continue over the coming months, with researchers aiming to move promising candidates toward human testing as quickly as safety allows.

Officials stress that while progress is encouraging, vaccine development remains a long-term process requiring strict regulatory review.